https://kstockbriefing.com
![[Disclosure] Samsung Biologics (207940) – Trading Suspension and Lifting of Suspension (Material Disclosure) / 2025-05-22](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a disclosure stating that its stock trading was temporarily suspended at 07:45 KST on May 22, 2025, due to a material disclosure (corporate spin-off decision), and was subsequently lifted at 09:30 KST on the same day following the release of the disclosure….
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has announced a decision to execute a simple spin-off (demerger), separating into a surviving entity focused on its CDMO business and a new entity (Samsung Episholdings Co., Ltd., provisional) dedicated to subsidiary management and investments. The surviving entity will undergo a listing change, while…
Read More “[Disclosure] Samsung Biologics (207940) – Decision on Corporate Spin-off / 2025-05-22” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary In conjunction with market measures on the underlying equity, trading of Samsung Biologics’ stock futures and options was temporarily suspended at 07:45 KST on May 22, 2025, and resumed at 09:30 KST on the same day following the lift of the suspension. 📊 [Key Disclosure Details…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange (KRX) has issued an inquiry request requiring Samsung Biologics to disclose an official response regarding press reports on a proposed corporate spin-off by May 22, 2025, at 12:00 KST. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
![[Disclosure] Celltrion (068270) – Decision on Acquisition of Treasury Shares / 2025-05-20](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환셀트리온.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire 649,351 common treasury shares (approx. KRW 100.0B) through open market purchases to stabilize share prices and enhance shareholder value, with plans to cancel all acquired shares. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is hosting an online IR conference on May 15, 2025, for domestic and international journalists, analysts, and institutional investors to outline business impacts from pharma policy shifts and its 2025 outlook. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 25,336 common shares on May 19, 2025, following the exercise of stock options. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (May 19, 2025) This disclosure details the…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to cancel 589,276 treasury common shares (valued at approx. KRW 98.6B) to stabilize stock prices and enhance shareholder value, with a scheduled cancellation date of May 21, 2025. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…
Read More “[Disclosure] Celltrion (068270) – Decision on Cancellation of Shares / 2025-05-12” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced its provisional Q1 2025 separate financial results, reporting revenue of approximately KRW 634.0B and operating profit of KRW 136.4B. While revenue and operating profit decreased compared to the previous quarter, operating profit grew by over 370% year-over-year. 📊 Key Disclosure Content & Financial Highlights…
Read More “[Disclosure] Celltrion (068270) – Provisional Sales Performance / 2025-05-09” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion reported its Q1 2025 consolidated provisional results with revenue of KRW 841.9B (+14.24% YoY) and operating profit of KRW 149.4B (+867.94% YoY). 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Final Audited Financial Figures in Upcoming Q1…